TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03230851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100mg/d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100mg/2d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/2d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 100mg/3d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 100mg/3d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 50mg bid therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 50mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 75mg/d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 75mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin 50mg/d therapy
Description: 100mg aspirin for at least 5 days followed by aspirin 50mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indobufen 100mg bid therapy
Description: 100mg aspirin for at least 5 days followed by indobufen 100mg bid
Study: NCT00918567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atomoxetine
Description: open label treatment dosed up to 1.8mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atomoxetine
Description: open label treatment dosed up to 1.8mg/kg/day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior Modification Therapy
Description: 8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
Study: NCT01173770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: Escalating single doses ADC3680B or Placebo over 5 study periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: Escalating single doses ADC3680B or Placebo over 5 study periods

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: ADC3680B or Placebo for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: ADC3680B or Placebo for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: ADC3680B or Placebo for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADC3680B
Description: Single doses ADC3680B over 2 study periods under fasted and fed conditions
Study: NCT02126865

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1060469
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469 Healthy
Description: tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1060469 asthmatics
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1060469 asthmatics
Description: tablet
Study: NCT01437865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadofosveset contrast agent enhanced MRI Axilla
Description: A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
Study: NCT01714648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.2 mg
Description: A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
Study: NCT01887626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg whole tablet
Description: Ticagrelor 90 mg whole tablet administered as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg tablet crushed
Description: Ticagrelor 90 mg crushed and suspended in water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube
Description: Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
Study: NCT05531409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Responsible Behavior for Younger Children (RBYC)
Description: RBYC is a school-based universal prevention program designed to provide adolescents and their parents (or other guardians) with the knowledge and tools to help adolescents interact appropriately with younger children and avoid engaging younger children in sexual behaviors.
Study: NCT00263809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pathogen Reduction Technology
Study: NCT00003313

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amifostine trihydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT00429806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: DHEA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02451605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic nerve blockade (Ropivacaine)
Description: Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic nerve blockade (Ropivacaine)
Description: Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic nerve blockade (Ropivacaine)
Description: Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement surgery.
Description: Total knee replacement surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement surgery.
Description: Total knee replacement surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement surgery.
Description: Total knee replacement surgery.
Study: NCT03286582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-203 1% Topical Ointment
Description: AC-203 1% ointment BID (twice daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol 0.05% Topical Ointment
Description: Clobetasol 0.05% Topical Ointment BID
Study: NCT01179919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Capsule, 75 mg by mouth for 9 doses
Study: NCT00169195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)
Study: NCT01507857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400U /0.5ml EV71 vaccine
Description: inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0/0.5ml placebo
Description: 0/0.5ml placebo, two doses, 28 days interval
Study: NCT03202836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: progesterone
Description: vaginal utrogestan

Intervention type: DRUG
Group type: OTHER
Intervention: Tocolytics
Description: tocolysis for 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocolytics
Description: tocolysis for 48 hours

Intervention type: DRUG
Group type: OTHER
Intervention: Steroids
Description: antenatal corticosteroids for 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: antenatal corticosteroids for 48 hours
Study: NCT02879019

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Stretching exercise group
Description: In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking training group
Description: Patients will perform two walking session per week, each consisting of 15\*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
Study: NCT01089647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and montelukast
Description: budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
Study: NCT04567342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 automated message
Description: Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 automated message
Description: Parents of eligible patients will receive 1 HIPAA compliant automated call or text reminder (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 automated messages
Description: Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 automated messages
Description: Parents of eligible patients will receive 2 HIPAA compliant automated call or text reminders (based on preference recorded in EHR) that their child is due for a checkup and information on how to schedule an appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No personal contact attempt
Description: No personal contact attempts will be made.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No personal contact attempt
Description: No personal contact attempts will be made.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 personal contact attempt
Description: Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1 personal contact attempt
Description: Parents of eligible patients will receive a text from a medical assistant informing them that their child is due for a check up. This will be followed by personal call from the medical assistant to assist the parent with scheduling an appointment.
Study: NCT04598243

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Smart Energy System
Description: A nutritional /herbal combination
Study: NCT00076050

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy isoflavones
Description: Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo soy isoflavones
Study: NCT01025037

Intervention type: DEVICE
Group type: OTHER
Intervention: Conexa Reconstructive Tissue Matrix
Description: Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
Study: NCT01462565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: current marketed FLOLAN (epoprostenol sodium)
Description: continuous intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: new thermo stable formulation of epoprostenol sodium
Description: continuous intravenous infusion
Study: NCT04743258

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAXILLARY PREMOLAR EXTRACTION
Description: Patients will undergo bilateral maxillary 1st premolar extraction before bonding followed by leveling \& alignment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DISTALIZATION
Description: Maxillary arch will be distalized with the help Zygomatic miniplates will be placed bilaterally.
Study: NCT02349165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial versus epithelium-off CXL
Description: A comparison of the CXL procedure with and without epithelium removal

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transepithelial versus epithelium-off CXL
Description: A comparison of the CXL procedure with and without epithelium removal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ricrolin TE
Description: Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic riboflavin
Description: After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
Study: NCT00128453

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine (for 3 months)
Description: Colchicine 0.5mg BID (patients\>70Kg) or 0.5mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT04085666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX 6114
Description: CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX 6114
Description: CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.
Study: NCT03436680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Complete neurofeedback training sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT00561730

Intervention type: DRUG
Intervention: Pantoprazole
Description: Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
Study: NCT03560375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT)
Description: Subjects will be allocated to CRT which consists of 10 resistance exercises for different body parts (=1 circuit) repeated 12-15 times, using modest weights (approximately 40-60% of one repetition maximum, RM). Each exercise is expected to be completed within 30-40 sec. The participant will move quickly (within 15-30 seconds) from one exercise to the next. The circuit will be repeated up to three times depending on the week of intervention. Thus, it will take about 30 min to complete an exercise session. For a summary of articles on CRT in older adults based on a meta-analysis, we performed please see:~Circuit resistance training is an effective means to enhance muscle strength in older and middle-aged adults: A systematic review and meta-analysis. Ageing Res Rev. 2017 Aug;37:16-27

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vegeterranean diet (V-Med diet)
Description: The modified V-Med diet will be considered as ad-libitum (using fat sources) aimed for a minimum of 1 gr/kg/day of protein, limiting carbohydrates: 3 servings for men and 2 servings for women per main meal and 1 serving per intermediate meal for both genders. Subjects will be asked to avoid red meat and poultry completely and the consumption of dairy and eggs products will be limited to 2 servings per day. 2-3 servings of fish should be consumed during the week. The rest of protein consumption will be recommended from legumes sources. The target legume consumption will be 1.5 cup per day (2 servings per day) of cooked beans, chickpeas, lentils and/or using pulses-based flour or pulses-based bread. Consumption of whole grain carbohydrate foods will be recommended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: Subjects allocated to empagliflozin will be asked to add empagliflozin 10mg, preferably in the morning, to their medication regimen. Subjects will be monitored for adverse events including hypoglycemic events during all study visits.
Study: NCT02642315

Intervention type: DRUG
Group type: OTHER
Intervention: Horizant
Description: Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 0, 30 and 90) during Phase I.~Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360).
Study: NCT03536117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MTBVAC
Description: Live-attenuated Mycobacterium tuberculosis based on the deletion of phoP and fadD26 virulence genes
Study: NCT00576901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m2 iv on day 1 of each 3 week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: 2000mg/m2 po on days 1-15 of each 3 week cycle
Study: NCT04471675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-bound docetaxel
Description: Albumin-bound docetaxel by intravenous infusion.
Study: NCT02746952

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCART19
Study: NCT03836066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab-Bevacizumab
Description: Atezoluzumab 1200 mg + Bevacizumab 15 mg / kg
Study: NCT02426957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational enhancement therapy
Description: The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
Study: NCT00004109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
Study: NCT03510364

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: For the feeding intervention, participants consumed a meal that contains 60% of their energy daily energy requirement as a lunch time meal for 14 consecutive days under observation except during the weekends. To ensure the participant receives 60% of the daily energy requirement as a lunch meal we added a supplemental shake to the standard 1200 kcal meal.
Study: NCT00298870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isoniazed
Description: Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
Study: NCT06355245

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Collection of blood samples
Study: NCT01345149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Description: Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Exercise
Description: Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.~Exercise: Individual counselling
Study: NCT04111744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Exercise Training
Description: Patients undergoing CABG and randomized to the Training Group complete six sessions of aerobic endurance training prior CABG surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Optimal medical therapy
Description: Standard medication for stable CAD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimal medical therapy
Description: Standard medication for stable CAD
Study: NCT04597086

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bright White Light Therapy
Description: Receive BWLT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies